Drugs / CART-EGFRvIII
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02209376 | Nov 2014 → Apr 2018 | — | University of Pennsylvania | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-EGFRvIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02209376 ↗ |
| Modality | Cell therapy | “autologous T cells transduced with a lentiviral vector” NCT02209376 ↗ |
| Route | Intravenous | “intravenous delivery of a single dose of autologous T cells” PMID 28724573 ↗ Jul 2017 |